This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

National Survey Identifies Potential Barriers To HIV Treatment Use In U.S.

RESEARCH TRIANGLE PARK, N.C., June 10, 2014 /PRNewswire/ -- ViiV Healthcare today announced new survey data that provide important insights that may help explain why HIV treatment rates remain low in the United States. Findings from the online survey, conducted by Harris Interactive on behalf of ViiV Healthcare in 2013, reveal gaps in knowledge about HIV and its treatment among diagnosed but untreated people living with HIV (PLWHIV), as well as misperceptions about HIV prescription medicine and fewer positive perceptions of overall well-being compared to those of PLWHIV who are treating their disease.

To view the multimedia assets associated with this release, please click:
National Survey Identifies Potential Barriers to HIV Treatment Use in U.S.

Both the U.S. Centers for Disease Control and Prevention and the Department of Health and Human Services recommend early treatment for the benefit of the HIV patient.[i] Still, many PLWHIV do not initiate therapy at the time of diagnosis, if at all. In fact, despite significant strides in HIV therapy and access, only 33 percent of the 1.1 million Americans living with HIV are taking the medicines they need to live longer, healthier lives and reduce the chance of passing the disease on to a partner.[ii]

"There is mounting evidence clearly establishing many personal and public health benefits that go along with HIV treatment. Earlier treatment and a suppressed viral load help reduce the number of new infections and slow the virus' ability to damage the body.[iii] But this survey shows that gaps in knowledge about treatment among people living with HIV may serve as potential barriers to antiretroviral therapy," said Julie Scofield, Executive Director, National Alliance of State & Territorial AIDS Directors. "Educating people about the importance and benefits of HIV treatment is critical, as is improving linkages to and retaining people in care – particularly in communities of color, where later-stage AIDS diagnoses are more common than earlier-stage HIV diagnoses."

The survey findings point to the following four potential barriers to treatment use by comparing the reported perceptions and experiences of HIV-positive adults (aged 18+) who had never taken a prescription medicine to treat their HIV ("untreated patients") to those who had begun taking a prescription medicine to treat their HIV in the past five years ("treated patients"):

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.05 -0.82%
FB $118.00 1.10%
GOOG $693.01 0.29%
TSLA $240.76 -2.81%
YHOO $36.60 0.03%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs